Tag: portola pharmaceuticals

May 28, 2019

8 Small Biotech ETFs

Want to invest in small biotech ETFs? Here we profile eight that life science investors may want to look into.
January 2, 2019

U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa

Portola Pharmaceuticals (Nasdaq:PTLA) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Prior Approval Supplement (PAS)...
September 12, 2018

U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process

Portola Pharmaceuticals (Nasdaq:PTLA) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Company’s Prior Approval Supplement...
March 23, 2018

Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

Portola Pharmaceuticals (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
March 13, 2018

Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent AndexXa

Portola Pharmaceuticals (Nasdaq:PTLA) announced new interim results from ANNEXA-4, the Company’s ongoing Phase 3b/4 trial of its investigational universal Factor Xa...
March 1, 2018

Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Portola Pharmaceuticals (NASDAQ:PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided a...
February 20, 2018

Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban

Portola Pharmaceuticals (Nasdaq:PTLA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...